---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-303995"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-12-27T23:59:59+00:00"
generated_at: "2026-06-07T07:10:54.818088+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MannKind restructures Amphastar supply deal: lowers annual commitments, adds capacity fees

## Summary
- Prior total purchase commitments of €58.7M for 2024-27 replaced; new commitments for 2024 = €2.9M, 2025 = €1.5M.
- Capacity fee introduced: €2M/year in Year 1 of new supply, decreasing to €500k/year in Years 6-9.
- Term extended to later of Dec 31, 2035 or completion of purchase commitments.
- Amendment accommodates change in source of inclusion bodies (insulin intermediate) to Amphastar-manufactured.

## SEC filing metadata
- accession: 0001193125-23-303995
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/0001193125-23-303995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/d57247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-303995
- JSON: https://secwatch.observer/filing/0001193125-23-303995.json
- Plain text: https://secwatch.observer/filing/0001193125-23-303995.txt

## Key facts
- Material Agreements
  MANNKIND CORP amended Seventh Amendment to Supply Agreement with Amphastar Pharmaceuticals, Inc. valued at €2.9 million annual purchase commitment for 2024; amended purchase commitments through 2035 (effective 2023-12-22).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Amphastar Pharmaceuticals, Inc.
  - Value: €2.9 million annual purchase commitment for 2024; amended purchase commitments through 2035
  - Effective: 2023-12-22
  source text: On December 22, 2023, MannKind Corporation (the “Company”) entered into a Seventh Amendment to Supply Agreement (the “Seventh Amendment”) with Amphastar Pharmaceuticals, Inc. pursuant to which the parties amended the Supply Agreement, dated July 31, 2014, as amended (the “Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/0001193125-23-303995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.